OAB-039: Treatment duration and long-term outcomes with daratumumab in transplant-ineligible newly diagnosed multiple myeloma from the phase 3 MAIA study

MLA

Philippe Moreau, et al. “OAB-039: Treatment Duration and Long-Term Outcomes with Daratumumab in Transplant-Ineligible Newly Diagnosed Multiple Myeloma from the Phase 3 MAIA Study.” Clinical Lymphoma Myeloma and Leukemia, vol. 22, Aug. 2022, pp. S23–24. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........fbfb53ff701d241786ed7db5b9b7a4e3&authtype=sso&custid=ns315887.

APA

Philippe Moreau, Thierry Facon, Saad Usmani, Shaji Kumar, Torben Plesner, Hartmut Goldschmidt, Robert Orlowski, Aurore Perrot, Ajai Chari, Gordon Cook, Huiling Pei, Rian Van Rampelbergh, J Blake Bartlett, Clarissa Uhlar, Robin Carson, & Nizar Bahlis. (2022). OAB-039: Treatment duration and long-term outcomes with daratumumab in transplant-ineligible newly diagnosed multiple myeloma from the phase 3 MAIA study. Clinical Lymphoma Myeloma and Leukemia, 22, S23–S24.

Chicago

Philippe Moreau, Thierry Facon, Saad Usmani, Shaji Kumar, Torben Plesner, Hartmut Goldschmidt, Robert Orlowski, et al. 2022. “OAB-039: Treatment Duration and Long-Term Outcomes with Daratumumab in Transplant-Ineligible Newly Diagnosed Multiple Myeloma from the Phase 3 MAIA Study.” Clinical Lymphoma Myeloma and Leukemia 22 (August): S23–24. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........fbfb53ff701d241786ed7db5b9b7a4e3&authtype=sso&custid=ns315887.